FARE - Food Allergy Research & Education Logo

Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease

Study Purpose

Single-center, case-control, longitudinal, observational, population based cohort study with stratified sample (by age group, gender, and residential area).

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Yes
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational [Patient Registry]
Eligible Ages 6 Years - 18 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Proven sensitization to at least one food allergen with a diagnosis of at least one allergic disease for at least one year.
  • - Clinical diagnosis of allergic rhinitis (AR) for at least 1 year with symptoms of the nose, induced after exposure to allergens via IgE-mediated hypersensitivity reactions (symptoms of watery rhinorrhea, nasal obstruction, nasal itching and sneezing).
  • - Diagnosis of atopic dermatitis (AD) with AD symptoms lasting for more than 3 months, with or without food allergy.
Additional

inclusion criteria:

• Significant clinical allergy to indoor and outdoor allergens, an food allergens with positive skin prick test (SPT) and specific IgE levels (>0.35kUA/L)

Exclusion Criteria:

  • - Known inborn or perinatal pulmonary disease; - Pulmonary malformation.
  • - Oxygen therapy after birth with a duration of more than 24 h.
  • - Ventilator support or mechanical ventilation after birth.
  • - Diagnosis of cystic fibrosis.
  • - Primary ciliary dyskinesia.
  • - Heart failure diagnosed after birth affecting pulmonary circulation.
  • - Major respiratory diseases such as e.g. interstitial lung disease and other congenital and serious chronic disease.
- Fever of at least 38.5 °C during the last two weeks prior to the planned visit

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05177744
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Children's Hospital Srebrnjak
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Recruiting
Countries Croatia
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Food Hypersensitivity, Asthma in Children, Rhinitis, Allergic, Dermatitis, Atopic
Additional Details

This study will involve schoolchildren (aged 6-18 years), population cohort based on differential exposure and susceptibility to allergy(paediatric population, allergic vs.#46; healthy subjects). participants will be selected based on proven sensitization to at least one food allergen (preferentially but not only to seafood) with a diagnosis of at least one allergic disease (i.e. allergic asthma, allergic rhinitis (AR), atopic dermatitis (AD) and/or food allergy) for at least a year. Subjects will be recruited from three distinct and different geographical regions in Croatia: 2 continental regions (Zagreb, urban) and Slavonia (urban and rural) and 1 Mediterranean region (urban and rural population), differing in the levels of exposure (allergens, pollutants), consumption of water (main water source- bottled water, public water source, well water), food consumption (food packed in plastic material, use of fertilizers in agriculture), nutrition (food from marine environments, industrially processed food, homegrown food) as well as different environmental protection measures and human activities.In each region and subgroup, we will recruit 70 allergic children and 140 healthy (non-allergic) children in a case-control study protocol, summing up to al total of 630 participants. The study will include visits: 1. Initial (screening) visit (V0 +3-6 months): written consent, assessment of inclusion and exclusion criteria, spirometry, Fractional exhaled nitric oxide (FeNO), questionnaires… 2. V2 (V0+6-9 months), questionnaires, environmental skin prick test (APT), sIgE (+ISAC), spirometry, FeNO, blood collection stool, 3. V2-V5 (V0+months 6-30 months)- regular visits (assessment) every 6 months, stool samples (second sampling) 4. Visit 4 (V0+18-24 months): environmental assessments, skin prick test (APT), sIgE (+ISAC), spirometry, FeNO, blood collection. 5. V5 (last visit, V0+24-30 months)- final assessment of the study outcome measures, check and document consumption, adherence, preventive measures, level of control, therapy correction. Participants in the control group will be involved in collaboration with other outpatient clinics (eg. from surgical outpatient clinics who have had minor surgical procedures, from the Otorhinolaryngology- Ear, Nose, Throat (ENT) outpatient clinics at least 7 days after acute ear inflammation or laryngitis, from emergency ambulatory patients at least 7 days after acute respiratory illness, etc.). All participants who will be included in the control group should have a negative history of allergic diseases, as well as other severe chronic diseases, including malignant, autoimmune, or mental illnesses. They will need to fulfil the ISAAC questionnaire for children perform spirometry and prick test with a standard palette of inhalational and nutritional allergens to exclude allergic diseases. No intervention tests or methods will be involved in this study. Patients who will be involved in the study will continue to take their regular therapy (according to guidelines) i.e. conduct treatment and all other non-therapeutic measures as if they were not involved in the study. Any deterioration or emergency intervention will be specifically evaluated and recorded as additional visits.

Arms & Interventions

Arms

: allergic (Zagreb, urban)

Participants will be selected based on proven sensitization to at least one food allergen (preferentially but not only to seafood) with a diagnosis of at least one allergic disease (i.e. allergic asthma, allergic rhinitis, atopic dermatitis and/or food allergy) for at least a year. Subjects will be recruited from continental region in Croatia - Zagreb (urban)

: healthy subjects (Zagreb, urban)

Healthy subjects that will be recruited from continental region in Croatia - Zagreb (urban). Negative history of allergic diseases, as well as other severe chronic diseases, including malignant, autoimmune, or mental illnesses.

: allergic (Slavonia, urban and rural)

Participants will be selected based on proven sensitization to at least one food allergen (preferentially but not only to seafood) with a diagnosis of at least one allergic disease (i.e. allergic asthma, allergic rhinitis, atopic dermatitis and/or food allergy) for at least a year. Subjects will be recruited from continental region in Croatia - Slavonia (urban and rural)

: healthy subjects (Slavonia, urban and rural)

Healthy subjects that will be recruited from continental region in Croatia -(Slavonia, urban and rural). Negative history of allergic diseases, as well as other severe chronic diseases, including malignant, autoimmune, or mental illnesses.

: allergic Mediterranean region (urban and rural population)

Participants will be selected based on proven sensitization to at least one food allergen (preferentially but not only to seafood) with a diagnosis of at least one allergic disease (i.e. allergic asthma, allergic rhinitis, atopic dermatitis and/or food allergy) for at least a year. Subjects will be recruited from mediterranean region in Croatia - urban and rural

: healthy subjects Mediterranean region (urban and rural population)

Healthy subjects that will be recruited from mediterranean region in Croatia -urban and rural. Negative history of allergic diseases, as well as other severe chronic diseases, including malignant, autoimmune, or mental illnesses.

Interventions

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Children's Hospital Srebrnjak, Zagreb, Croatia

Status

Recruiting

Address

Children's Hospital Srebrnjak

Zagreb, , 10000

Site Contact

Mirjana Turkalj, MD, PhD

mturkalj@bolnica-srebrnjak.hr

+38516391164

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.